Ajanta Pharmaceuticals Q2 Results Live: Profit Rises by 10.84% YoY
Ajanta Pharmaceuticals Q2 Results Live: Revenue increased by 15.38% YoY & profit increased by 10.84% YoY.
Ajanta Pharmaceuticals Q2 Results Live : Ajanta Pharmaceuticals declared their Q2 results on 28 Oct, 2024, reporting a topline increase of 15.38% year-over-year and a profit increase of 10.84% YoY. However, when compared to the previous quarter, the revenue grew by only 3.64%, while the profit saw a significant decrease of 11.92%.
The company's Selling, General & Administrative expenses saw a decline of 8.04% quarter-over-quarter, although they increased by 17.41% year-over-year, indicating some cost control measures are being implemented.
Operating income also showed positive growth, up by 2.04% q-o-q and 17.7% YoY, highlighting the company's ability to maintain operational efficiency despite fluctuating expenses.
Earnings per Share (EPS) for Q2 stood at ₹17.26, reflecting an increase of 11.35% compared to the same quarter last year, which is a positive indicator for investors.
In terms of stock performance, Ajanta Pharmaceuticals has delivered a -6.93% return in the last week, but a robust 32.09% return over the last six months and a remarkable 40.26% year-to-date return.
The company's current market capitalization is ₹36,506.81 crore, with a 52-week high of ₹3,485 and a low of ₹1,730.90, illustrating significant volatility in its stock price.
As of 29 Oct, 2024, analysts' ratings reflect a mixed sentiment: out of 9 analysts covering the company, 2 have given a Strong Sell rating, 1 has a Hold rating, 4 have a Buy rating, and 2 have issued Strong Buy ratings.
The consensus recommendation as of 29 Oct, 2024, is to Buy, indicating a generally optimistic outlook for Ajanta Pharmaceuticals despite recent market fluctuations.
Ajanta Pharmaceuticals Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 1186.64 | 1144.92 | +3.64% | 1028.44 | +15.38% |
| Selling/ General/ Admin Expenses Total | 260.96 | 283.78 | -8.04% | 222.27 | +17.41% |
| Depreciation/ Amortization | 34.39 | 33.97 | +1.24% | 33.71 | +2.02% |
| Total Operating Expense | 884.21 | 848.54 | +4.2% | 771.49 | +14.61% |
| Operating Income | 302.43 | 296.38 | +2.04% | 256.95 | +17.7% |
| Net Income Before Taxes | 290.24 | 322.12 | -9.9% | 275.94 | +5.18% |
| Net Income | 216.48 | 245.77 | -11.92% | 195.3 | +10.84% |
| Diluted Normalized EPS | 17.26 | 19.53 | -11.62% | 15.5 | +11.35% |
Stay updated on quarterly results with our results calendar
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
Business NewsCompaniesCompany ResultsAjanta Pharmaceuticals Q2 Results Live: Profit Rises by 10.84% YoY
FAQs
₹216.48Cr
₹1186.64Cr
First Published:29 Oct 2024, 10:56 AM IST
- Top Gainers
- Top Losers
- 52 Week High